Cholestech Looks To Capitalize On Possible OTC Switch For Cholesterol Drugs
This article was originally published in The Gray Sheet
Executive Summary
Cholestech is poised to ink a cosponsorship agreement with J&J/Merck for its Cholestech L.D.X. in vitro diagnostic should the drug partnership's Mevacor be cleared for over-the-counter use to reduce cholesterol.
You may also be interested in...
Lifestream Privalink Personalizes Cardiac Risk Assessment Via Internet
Lifestream Technologies plans to launch by March its Privalink system, integrating testing of total cholesterol with encrypted data transfer and record storage via the Internet.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.